https://www.keytruda.com/financial-support/
https://www.merck.com/news/fda-approves-expanded-indication-for-mercks-keytruda-pembrolizumab-in-locally-advanced-cutaneous-squamous-cell-carcinoma-cscc/#:~:text=The%20most%20common%20adverse%20reactions,of%20192%20patients%20with%20HNSCC.
https://clinicaltrials.gov/study/NCT03284424
https://www.empr.com/news/unloxcyt-approved-for-advanced-cutaneous-squamous-cell-carcinoma/
https://ir.checkpointtx.com/news-events/press-releases/detail/6/checkpoint-therapeutics-announces-completion-of-enrollment
https://ir.checkpointtx.com/news-events/press-releases/detail/15/checkpoint-therapeutics-announces-positive-interim-results
https://checkpointtx.com/wp-content/uploads/2024/12/uspi-unloxcyt.pdf
https://ir.checkpointtx.com/news-events/press-releases/detail/102/checkpoint-therapeutics-announces-cosibelimab-longer-term
https://ir.checkpointtx.com/news-events/press-releases/detail/86/checkpoint-therapeutics-announces-positive-interim-results
https://d1io3yog0oux5.cloudfront.net/_53cf2fe8723dd2674f1e49046ef3a5dc/checkpointtx/db/856/7551/pdf/Checkpoint+Presentation_CKPT_Dec+2024.pdf
https://ir.checkpointtx.com/news-events/press-releases/detail/127/checkpoint-therapeutics-announces-fda-approval-of
https://clinicaltrials.gov/study/NCT03212404?term=cosibelimab&rank=2
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cosibelimab-ipdl-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma
Accessed 12/18/24
